Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Octapharma.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Octapharma
Switzerland Flag
Country
Country
Switzerland
Address
Address
Octapharma AG, Seidenstrasse 2 8853 Lachen
Telephone
Telephone
+41 55 451 2121

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Wilate (von Willebrand factor and coagulation factor VIII) promotes platelet aggregation and platelet adhesion on damaged vascular endothelium for the treatment and control of bleeding episodes and perioperative management of bleeding.


Lead Product(s): Human Von Willebrand Factor/Coagulation Factor VIII Complex

Therapeutic Area: Genetic Disease Product Name: Wilate

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Octaplas® is human pooled plasma for infusion of pharmaceutical grade with standardised quality and unique safety profiles used for indications such as in hepatic failure or massive transfusion, substitution therapy in coagulation factor deficiencies etc.


Lead Product(s): Human Pooled Plasma

Therapeutic Area: Rare Diseases and Disorders Product Name: Octaplas

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 02, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

wilate® (human von willebrand factor/coagulation factor VIII complex) is a high-purity human VWF/FVIII concentrate, that undergoes two virus inactivation steps during its production. No albumin is added as a stabiliser.


Lead Product(s): Human Von Willebrand Factor/Coagulation Factor VIII Complex

Therapeutic Area: Genetic Disease Product Name: Wilate

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 05, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Octagam (human immune globulin) 10% is a liquid preparation of highly purified human immunoglobulin for intravenous administration. The results of the study demonstrated that octagam® 10% is an efficacious and well-tolerated treatment for adults with dermatomyositis.


Lead Product(s): Human Immune Globulin

Therapeutic Area: Immunology Product Name: Octagam

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 06, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

OCTA101, (a human-cl rhFVIII and recombinant human von Willebrand Factor fragment dimer/OCTA8) a recombinant FVIII developed for subcutaneous administration in adult patients with severe haemophilia A.


Lead Product(s): OCTA8,OCTA12

Therapeutic Area: Genetic Disease Product Name: OCTA101

Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 04, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

U.S. FDA Office of Orphan Products Development has awarded seven years of marketing exclusivity for Octagam® 10%, the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis.


Lead Product(s): Human Immune Globulin

Therapeutic Area: Immunology Product Name: Octagam

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 30, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

NUWIQ is a recombinant antihemophilic factor [coagulation factor VIII] indicated in adults and children with Hemophilia A for treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.


Lead Product(s): Simoctocog Alfa

Therapeutic Area: Genetic Disease Product Name: Nuwiq

Highest Development Status: ApprovedProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 05, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

MOTIVATE trial comprised regimens of human cell line-derived recombinant FVIII Nuwiq® or the plasma-derived FVIII products octanate® or wilate® for the management of patients with hemophilia A and inhibitors.


Lead Product(s): Simoctocog Alfa

Therapeutic Area: Genetic Disease Product Name: Nuwiq

Highest Development Status: ApprovedProduct Type: Large molecule

Recipient: Hämophilie-Zentrum Rhein Main

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The supplement approvals resulted in new product labeling for Octaplas™, Pooled Plasma (Human), Solvent/Detergent (S/D) Treated Solution for Intravenous Infusion, and fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution.


Lead Product(s): Human fibrinogen

Therapeutic Area: Hematology Product Name: Fibryga

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 29, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The NuProtect study was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq®.


Lead Product(s): Simoctocog Alfa

Therapeutic Area: Genetic Disease Product Name: Nuwiq

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 22, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY